LEADER 01476nam2-2200397---450- 001 990002759820203316 005 20100419093233.0 010 $a88-8265-361-7 035 $a000275982 035 $aUSA01000275982 035 $a(ALEPH)000275982USA01 035 $a000275982 100 $a20060616h2006----km-y0itay50------ba 101 0 $aita 102 $aIT 105 $aa|||z|||001yy 200 1 $aRilievi architettonici fittili d'etą imperiale dalla Campania$fGiuseppe Pellino 210 $aRoma$cL'Erma di Bretschneider$dcopyr. 2006 215 $a74 p., XX p. di tav.$cill.$d28 cm 225 2 $aStudi della Soprintendenza archeologica di Pompei$v13 300 $aIn testa al front.: Ministero per i beni e attivitą culturali, Soprintendenza archeologica di Pompei 410 0$1001000271620$12001$aStudi della Soprintendenza archeologica di Pompei$v, 13 606 0 $aDecorazione architettonica$yCampania$xSec. 1 a.C.-5. 606 0 $aTerrecotte architettoniche$xCollezioni 606 0 $aRilievi fittili$xCollezioni 676 $a729.5 700 1$aPELLINO,$bGiuseppe $0593579 801 0$aIT$bsalbc$gISBD 912 $a990002759820203316 951 $aXI.5. Coll.10/ 10$b190092 L.M.$cXI.5.$d00130369 959 $aBK 969 $aUMA 979 $aANNAMARIA$b90$c20060616$lUSA01$h1142 979 $aANNAMARIA$b90$c20100419$lUSA01$h0932 996 $aRilievi architettonici fittili d'etą imperiale dalla Campania$9998080 997 $aUNISA LEADER 00831nam0-22002891i-450 001 990000973140403321 005 20221212143602.0 035 $a000097314 035 $aFED01000097314 035 $a(Aleph)000097314FED01 100 $a20000920d1974----km-y0itay50------ba 101 0 $aeng 200 1 $aMezzogiorno$erealtą sociale e universitą$fdi Franco Catalano e Ermanno Rea 210 $aMilano$cBompiani$d1974 610 0 $aScuola [e] societą 676 $a370$v23$zita 700 1$aCatalano,$bFranco$f<1915-1990>$022113 702 1$aRea,$bErmanno$f<1927-2016> 801 0$aIT$bUNINA$gREICAT$2UNIMARC 901 $aBK 912 $a990000973140403321 952 $a1F-102$b9993$fFI1 952 $aFONDO ROSSI 1945$bROSSI 2017$fFARBC 959 $aFI1 959 $aFARBC 996 $aMezzogiorno$9352935 997 $aUNINA LEADER 05985nam 2200733Ia 450 001 9910784615103321 005 20230120004931.0 010 $a9780080549774 (Electronic Book) 035 $a(CKB)1000000000383609 035 $a(EBL)307154 035 $a(OCoLC)173609891 035 $a(SSID)ssj0000141668 035 $a(PQKBManifestationID)11147204 035 $a(PQKBTitleCode)TC0000141668 035 $a(PQKBWorkID)10057101 035 $a(PQKB)10104923 035 $a(SSID)ssj0001405295 035 $a(PQKBManifestationID)12625050 035 $a(PQKBTitleCode)TC0001405295 035 $a(PQKBWorkID)11387202 035 $a(PQKB)11632783 035 $a(MiAaPQ)EBC307154 035 $a(Au-PeEL)EBL307154 035 $a(CaPaEBR)ebr10186707 035 $a(EXLCZ)991000000000383609 100 $a20020118d2007 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aDrugs during pregnancy and lactation$b[electronic resource] $ehandbook of prescription drugs and comparative risk assessment : with updated information on recreational drugs, diagnostic procedures, vaccinations, poisoning, workplace and environmental contaminants, and breastfeeding during infectious disease /$fedited by Christof Schaefer 205 $a2nd ed. 210 $aAmsterdam ;$aNew York $cElsevier$d2007 215 $a1 online resource (907 p.) 300 $aDescription based upon print version of record. 311 0 $a9780444520722 (Cloth/HB) 320 $aIncludes bibliographic references and index. 327 $aFront cover; Drugs During Pregnancy and Lactation, Second edition; Copyright page; Contents; List of contributors; Preface; Notice; Chapter 1 General commentary on drug therapy and drug risks in pregnancy; 1.1 Introduction; 1.2 Development and health; 1.3 Reproductive stages; 1.4 Reproductive and developmental toxicology; 1.5 Basic principles of drug-induced reproductive and developmental toxicology; 1.6 Effects and manifestations; 1.7 Pharmacokinetics in pregnancy; 1.8 Passage of drugs to the unborn and fetal kinetics; 1.9 Causes of developmental disorders 327 $a1.10 Embryo/fetotoxic risk assessment1.11 Classification of drugs used in pregnancy; 1.12 Paternal use of medicinal products; 1.13 Communicating the risk of drug use in pregnancy; 1.14 Risk communication prior to pharmacotherapeutic choice; 1.15 Risk communication regarding the safety (or otherwise) of drugs already used in pregnancy; 1.16 Teratology information centers; Chapter 2 Specific drug therapies during pregnancy; 2.1 Analgesics and anti-inflammatory drugs; 2.1.1 Paracetamol (acetaminophen); 2.1.2 Aspirin (acetylsalicylic acid); 2.1.3 Pyrazolone derivatives 327 $a2.1.4 Combination analgesic preparations2.1.5 Opioid analgesics in general; 2.1.6 Morphine; 2.1.7 Codeine; 2.1.8 Pethidine (meperidine); 2.1.9 Fentanyl, alfentanil, remifentanil, and sufentanil; 2.1.10 Other narco-analgesics and centrally acting analgesics; 2.1.11 Naloxone; 2.1.12 Nonsteroidal anti-inflammatory drugs (NSAIDs); 2.1.13 Selective cyclooxygenase-2 (COX-2) inhibitors; 2.1.14 Migraine medications; 2.1.15 Additional analgesics; 2.1.16 Additional antiphlogistics and antirheumatics; 2.1.17 Myotonolytics; 2.1.18 Gout interval therapy; 2.1.19 Gout attack therapy 327 $a2.2 Antiallergic drugs and desensitization2.2.1 Antihistamines (H[sub(1)]-blocker); 2.2.2 Glucocorticosteroids; 2.2.3 Mast cell stabilizers; 2.2.4 Immunotherapy; 2.3 Antiasthmatic and cough medication; 2.3.1 Asthma and pregnancy; 2.3.2 Selective ?[sub(2)]-adrenergic agonists; 2.3.3 Corticosteroids; 2.3.4 Anticholinergic drugs; 2.3.5 Theophylline; 2.3.6 Cromoglycate, nedocromil, and lodoxamide; 2.3.7 Other mast cell inhibitors; 2.3.8 Antileukotrienes; 2.3.9 Monoclonal antibodies and other asthma medications; 2.3.10 Expectorants and mucolytic agents; 2.3.11 Antitussives 327 $a2.3.12 Non-selective ?-adrenergic agonists2.4 Antiemetics; 2.4.1 Nausea and vomiting in pregnancy; 2.4.2 Diet manipulations and treatment; 2.4.3 Complementary treatment options; 2.4.4 Acupuncture and acupressure; 2.4.5 Hypnosis; 2.4.6 Ginger; 2.4.7 Antihistamines (H[sub(1)]-blockers); 2.4.8 Dopamine antagonists; 2.4.9 Pyridoxine (vitamin B[sub(6)]); 2.4.10 Thiamine (vitamin B[sub(1)]); 2.4.11 Serotonin antagonists; 2.4.12 Glucocorticoids; 2.4.13 Other agents with antiemetic properties; 2.5 Gastrointestinal and antilipidemic agents and spasmolytics 327 $a2.5.1 Gastritis and peptic ulcer during pregnancy 330 $aThe latest edition is the resource for any practicing OB/GYN, family physician, midwife, or pharmacist who prescribes medicinal products to or evaluates environmental or occupational exposures in women who are or may become pregnant. Based on the highly successful seven German editions of this reference, the up-to-date drug listings have been revised into a handy pocket guide color tabbed for quick access to important information. Easy to reference each drug is listed discussing the side effects, general impact on organ systems, potential toxicity, and risks before offering dosage recom 606 $aPregnant women$xDrug use 606 $aPregnant women$xMedical care 606 $aObstetrical pharmacology$vHandbooks, manuals, etc 606 $aFetus$xEffect of drugs on$vHandbooks, manuals, etc 606 $aNewborn infants$xEffect of drugs on$vHandbooks, manuals, etc 615 0$aPregnant women$xDrug use. 615 0$aPregnant women$xMedical care. 615 0$aObstetrical pharmacology 615 0$aFetus$xEffect of drugs on 615 0$aNewborn infants$xEffect of drugs on 676 $a618.32 701 $aSchaefer$b Christof$01579019 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910784615103321 996 $aDrugs during pregnancy and lactation$93858779 997 $aUNINA